![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Cardiovascular Research Institute, Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania (L.A.N., A.D., T.H., L.Z., Y.-T.S., R.P.S.); and University of Massachusetts School of Medicine, Worcester, Massachusetts (D.E.)
We have recently demonstrated the benefits of glucagon-like peptide-1 (GLP-1) in enhancing regional and global myocardial function after reperfusion in the clinical setting of acute myocardial infarction. We hypothesized that GLP-1 facilitates recovery from myocardial stunning after an ischemic event. To investigate this, we administered GLP-1 (1.5 pmol/kg/min) to six dogs undergoing 10-min occlusion of the left circumflex coronary artery, followed by 24-h reperfusion. We compared the responses of coronary blood flow and regional thickening of the posterior wall with a group of eight vehicle-treated dogs undergoing the same occlusion-reperfusion protocol. Although recovery of coronary blood flow was identical, regional wall motion recovery occurred significantly (*p < 0.05) earlier (92 ± 4 versus 57 ± 5%* at 15 min) and was complete in the GLP-1-treated dogs, whereas residual contractile dysfunction persisted in the control group (99 ± 4 versus 78 ± 3%* at 24 h). This phenomenon was independent of changes in systemic hemodynamics or global systolic function. However, isovolumic left ventricular relaxation improved significantly in GLP-1-treated dogs. GLP-1 caused an insulinotropic effect, but no hypoglycemia. We conclude that GLP-1 enhances recovery from ischemic myocardial stunning after successful reperfusion.
Address correspondence to: Dr. Richard P. Shannon, Department of Medicine, Allegheny General Hospital, 320 East North Ave., Pittsburgh, PA 15212. E-mail: rshannon{at}wpahs.org
This article has been cited by other articles:
|
|
 |
|
  R. Abu-Hamdah, A. Rabiee, G. S. Meneilly, R. P. Shannon, D. K. Andersen, and D. Elahi The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1843 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Bergman, T. Tsvetkova, B. Lowes, and E. E. Wolfel Myocardial glucose and lactate metabolism during rest and atrial pacing in humans J. Physiol., May 1, 2009; 587(9): 2087 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Noyan-Ashraf, M. A. Momen, K. Ban, A.-M. Sadi, Y.-Q. Zhou, A. M. Riazi, L. L. Baggio, R. M. Henkelman, M. Husain, and D. J. Drucker GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice Diabetes, April 1, 2009; 58(4): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Timmers, J. P.S. Henriques, D. P.V. de Kleijn, J. H. DeVries, H. Kemperman, P. Steendijk, C. W.J. Verlaan, M. Kerver, J. J. Piek, P. A. Doevendans, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol., February 10, 2009; 53(6): 501 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. G. Webb, R. Williams, and M. S. Marber Lizard spit and reperfusion injury. J. Am. Coll. Cardiol., February 10, 2009; 53(6): 511 - 513. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Hausenloy and D. M. Yellon GLP-1 Therapy: Beyond Glucose Control Circ Heart Fail, September 1, 2008; 1(3): 147 - 149. [Full Text] [PDF]
|
|
|
|
|
|
I. Poornima, S. B. Brown, S. Bhashyam, P. Parikh, H. Bolukoglu, and R. P. Shannon Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat Circ Heart Fail, September 1, 2008; 1(3): 153 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ban, M. H. Noyan-Ashraf, J. Hoefer, S.-S. Bolz, D. J. Drucker, and M. Husain Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor-Dependent and -Independent Pathways Circulation, May 6, 2008; 117(18): 2340 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, Y.-T. Shen, and R. P. Shannon Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1106 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Nikolaidis, D. Elahi, Y.-T. Shen, and R. P. Shannon Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2401 - H2408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
